Maraciclatide

Drug Profile

Maraciclatide

Alternative Names: 99mTc-maraciclatide; 99mTc-NC100692; GE-078; NC-100692; Tc-99m-NC100692; Tc99m-Maraciclatide; TcNC100692

Latest Information Update: 11 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GE Healthcare
  • Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiovascular disorders
  • Clinical Phase Unknown Breast cancer

Most Recent Events

  • 11 Sep 2015 Clinical development is ongoing in USA and United Kingdom
  • 04 Sep 2014 NHS Foundation Trust plans a phase I trial for Osteitis deformans diagnosis in England (UKCRN17360)
  • 01 Feb 2014 GE Healthcare completes a clinical trial in Breast cancer diagnosis in USA (NCT00888589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top